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Background: The aim of the study was to estimate the prevalence of depression in the population diagnosed with
diabetes type 2 and to test the hypothesis that the presence of depression in such cases was associated with a) worse
glycaemic control, and b) higher healthcare costs.
Methods: We conducted a cross-sectional analysis, from 1st September 2010 to 31st August 2011, among patients with
type 2 diabetes aged 35 years and over in the Basque Country. It was identified how many of them had also depression.
The database included administrative individual level information on age, sex, healthcare costs, other comorbidities, and
values of glycaemic control (HbA1c). Deprivation index variable was used as socioeconomic measure and, to observe the
coexistent pathologies, all the patients diagnoses were categorized by Adjusted Clinical Groups. We used a measure of
association, a logistic and a linear regression for analysis.
Results: 12.392 (9.8%) of type 2 diabetes patients were diagnosed with depression, being the prevalence 5.2% for males
and 15.1% for females. This comorbidity was higher among the most deprived population. There was no association
between the presence of depression and glycaemic control. We estimated that the comorbidity average cost per
patient/year was 516€ higher than in patients with just type 2 diabetes (P < 0.001) adjusted by the other covariates.
Conclusions: We did not find any relationship between depression and glycaemic control in patients with type 2
diabetes. However, the comorbidity was associated with significantly high healthcare costs compared to that of type 2
diabetes occurring alone, after adjusting by other illness. Thus, there is a need of more precise recognition, screening
and monitoring of depression among diabetic population. Evidence-based treatment for depression should be included
in type 2 diabetes clinical guidelines.
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The social and economic burden of type 2 diabetes is a
matter of concern for many health systems worldwide.
According to a recent study, the prevalence of type 2
diabetes in Spain is 13.8% in the population above
18 years old [1]. Moreover, incidence and prevalence of
diabetes mellitus along with other chronic diseases is
constantly growing [2] and in recent decades, this prob-
lem is exacerbated by the presence of other chronic* Correspondence: edurne.almo@gmail.com
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as depression [4].
Depression is the most common mental disorder and
generates a great impact on the individual, family and
society in terms of suffering, disability and economic
costs, a phenomenon that seems to occur in many parts
of the world. Depression is estimated to affect 350 mil-
lion people worldwide [5] and it also causes a large
increase in all-cause mortality risk (up to 70%) [6], at the
same time being the most expensive mental disorder in
Europe [7].
According to several studies, presence of additional
diagnosis of depression in patients with type 2 diabetes
can negatively influence control, treatment and outcomesCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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[9] conducted in 2007, combination of two or more
chronic conditions with depression obtained the lowest
scores making diabetes and its complications the worst
combination for depression (comparing it to combin-
ation of depression with other chronic conditions such
as asthma or angina), in terms of the worst quality of life
and disability.
However, data about relations of diabetes and depres-
sion ranges widely, depending on the type of diabetes
and the fact whether depression is self-reported or clin-
ically justified [10]. Moreover, the influence of one dis-
ease in the aetiology of the other is most likely to have
bidirectional character [11,12]. Depression as a baseline
disease can increase incidence of type 2 diabetes through
increasing vulnerability to various type 2 diabetes associ-
ated factors. Latest meta-analysis [13] of comorbidity of
these two diseases suggests that depression and diabetes
may co-occur due to shared biochemical changes in hor-
monal system and psychological burden of chronic disease.
Another study reported that the prevalence of depression
among patients with type 2 diabetes is twice than in gen-
eral population, 19.1% and 10.7% respectively [14].
Several studies have shown that the following socio-
demographic associated factors can be predictive of hav-
ing depression among type 2 diabetes patients: female
sex, younger age, lower socioeconomic status, being un-
married, poor social support, certain ethnicities [9]. Fur-
thermore, depression is associated with non-adherence
to diabetes self-care such as following dietary restrictions,
medication compliance, and blood glucose monitoring,
resulting in worse overall clinical outcomes [11].
In time of recent years, there have been many studies
presenting evidence that comorbid depression among in-
dividuals with type 2 diabetes is associated with poor
diabetes outcomes. A meta-analysis of 24 studies found
that depression was significantly associated with poor
glycaemic control in individuals with type 2 diabetes
[15]. Richardson et al. [16] found that in over 4 years of
follow-up there was a significant longitudinal relation-
ship between depression and glycaemic control, and that
depression was associated with persistently higher HbA1c
levels over the time period. Other review detected that dia-
betes self-care did not fully account for the relationship be-
tween depression and HbA1c levels [17].
In economic terms, recent studies indicate increased
healthcare utilization and healthcare costs among indi-
viduals with comorbidity of diabetes and depression.
One study found that patient with diabetes and depression
had higher diabetes-related total medical costs (14,253€)
than patients with diabetes alone (3,559€) [18]. Another
study showed that individuals with diabetes and depression
had 2 times higher health care costs compared with those
who did not have depression [19].This study aims to estimate the prevalence of depres-
sion in the population diagnosed with type 2 diabetes.
Furthermore, to establish the relationship between de-
pression as comorbidity in patients with type 2 diabetes
and glycaemic control, and to test the impact on health-
care cost.
Methods
The study protocol was approved by the Ethical Commit-
tee of Clinical Research of Euskadi (PI2014074), Spain. The
informed consent was not obtained because patient health
record was anonymized and de-identified prior to analysis.
Data source and design
We conducted a descriptive cross-sectional analysis in
which we used the database of the population stratifica-
tion program of the Basque Health Service – Osakidetza
[20]. Although this programme began in 2010, with the
aim of classifying all inhabitants of the autonomous re-
gion in terms of their future healthcare needs, the data-
base (PREST) contains information collected since 2007
and includes every citizen covered by the public health
insurance in the Basque Country, regardless of whether
they had made any contact with or use of the Basque
Health Service. That is, practically all the inhabitants of
the Basque Country are included.
PREST was assembled combining information on in-
dividuals from several sources (primary and specialized
health care records, computerised files from day hospi-
tals, emergency departments’ registries, hospital discharge
reports, and census data) and involves the following
data:
 Demographic data: age, sex and census area of
residence.
 A register for any contact of the patients with
Osakidetza, containing the type of service provided,
codes for diagnoses and information on significant
procedures (such as dialysis, radiation therapy,
chemotherapy or rehabilitation therapies).
 Prescriptions in primary care.
Services for which no information was available com-
prise: non-acute Mental Health (both admissions and
outpatient visits), hospital-at-home services, medical
transport, prostheses and other equipment delivered to
patients at home.
In Spain, according to the Health Ministry’s regulation
[21], diagnoses and procedures are codified by means
of the ICD-9-CM system [22], while the Anatomical
Therapeutic Chemical coding system (ATC) [23] is used
for drugs prescription.
Taking into account all this information, Basque citizens
are annually classified using the Johns Hopkins Adjusted
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enables health problems to be identified from diagnoses
and prescriptions and patients to be categorized according
to their health care needs.
Using the above mentioned resources, the observed
population consisted of patients who have been covered
by the Basque Country’s public health insurance for at
least 6 months prior to period of study (dated from 1st
of September in 2010 to 31st of August in 2011), inde-
pendently if patients had visited doctors or health cen-
ters of Osakidetza during such period.
So, firstly, we identified diabetes mellitus patients who
were ≥ 35 years old because diabetes type 2 is uncom-
mon at younger ages [25]. It was considered to have dia-
betes mellitus, those who had either being prescribed with
oral anti-diabetics drugs or had any kind of diabetes-
related diagnose or its complications, before 31st of August
2011; of them were excluded all people who had one or
more diagnosis related to type 1 diabetes or with non-
specified diabetes treated exclusively with insulin.
Secondly, we identified those patients with depression
diagnosed either in Primary Care and hospital settings.
Often these health professionals do not perform in their
diagnoses a description precise enough to allow differen-
tiation between different types of depressive disorders
and, therefore, we accepted the presence of any of them.
Since the database contains information of a period of
4 years, in order to exclude those episodes that are not
currently active, we looked only for patients who had a
diagnosis of depression in last 12 months or had re-
peated prescriptions of antidepressants during at least
four months in the last year.
Variables and analysis
Since many people had more than one measurement of
glycated haemoglobin, the last measurement registered
in the period analyzed was used. The values of HbA1c
were divided into four groups according to the study of
Berkowitz et al. [26], these groups were: ≤7% (group 1),
between >7% and ≤8% (group 2), between >8% and ≤9%
(group 3) and finally >9% (group 4).
In order to take into account the presence of comor-
bidities, we used Aggregated Diagnosis Groups (ADGs),
which is the component of the Johns Hopkins ACG
case-mix system. ADG consists of 32 categories, specif-
ically designed to aggregate diagnoses into groups with
similar severity, duration of condition, and treatment
needs. A more complete description of this methodology
can be found in the bibliography [24].
The deprivation index of the census tract (median
population size is equal to 1,200 inhabitants) of resi-
dence proposed by the MEDEA project [27] was used as
a proxy for individual socioeconomic position. Its calcu-
lation takes into account the percentages of residents whoare manual workers, unemployed, temporary employees,
or have not finished primary school, overall and also specif-
ically among young people, given the most recent Census
available. According to such index, tracts are ordered and
categorized into quintiles (the fifth one corresponds to the
most deprived areas and the first one to the less unfavour-
able conditions). This index is not specific to the ages
groups observed in this study; however, it provides a meas-
ure of the level of access to material and social resources in
a community and has been shown to be correlated with
general rates of mortality [28] and morbidity, even in par-
ticular population groups, as the elderly [29]. Although
been elaborated in 2008 (from Census data collected in
2001), and from then it is likely that the values of the
observed variables percentages have experienced varia-
tions, it is conceivable that the relative position of each
area in respect to the others have not suffered relevant
alterations; in fact, in recent years it has been proved
that the deprivation index is related to the health of the
resident inhabitants [30,31].
Health care utilization costs were also estimated for the
period of study. For variables such as visits to Accident &
Emergency (A & E), rehabilitation sessions, outpatient care,
primary care visits, laboratory tests and radiological exami-
nations ordered by primary care, and various outpatient
procedures (dialysis, radiotherapy and chemotherapy);
the number of services used by each patient was multi-
plied by standardized costs (the average cost of each ser-
vice provided to a patient treated in Osakidetza, according
to calculations made by the aforementioned organisation).
We estimated healthcare costs of primary care pre-
scriptions recorded in electronic health records based on
the market value of the drugs. The costs of hospitalisa-
tion and outpatient surgery were calculated in relation to
their cost-weights in the corresponding Diagnosis-Related
Groups (DRGs).
Means and standard deviation of continuous variables
and frequencies of ordinal or categorical variables were
calculated during the study, stratifying by sex and age
band. Statistical significance test (test of Pearson X2)
was calculated to establish the relationship between
presence or absence of comorbidity and other variables
such as sex, age band, socioeconomic level and glycaemic
control. Logistic regression analysis was performed to
see the associated factors to depression in patients with
diabetes type 2 using as independent variables HbA1c
categories, sex, age band, ADGs and deprivation index.
Finally, linear regression was used to see how many, on
average, of the total cost is imputable to depression,
HbA1c categories, sex, age band, ADGs and deprivation
index.
Analysis was conducted on STATA, Data Analysis and
Statistical Software, Release 12 (StataCorp, LP, College
Station, TX).
Table 1 Distribution of patients with diabetes type 2 and
with comorbidity (depression and type 2 diabetes)
Males Females
N % N %
Patients with type 2
diabetes mellitus
Age band
Age < 65 25,813 39.8 12,771 25.8
Age ≥ 65 39,122 60.3 36,796 74.2
Deprivation index
1 10,757 16.6 7,267 14.7
2 13,032 20.1 9,207 18.6
3 13,402 20.6 9,980 20.1
4 13,953 21.5 10,970 22.1
5 13,791 21.2 12,143 24.5
Total 64,935 49,567
HbA1c
1 (≤7%) 32,193 65.4 23,620 62.4
2 (>7% & ≤8%) 10,148 20.6 8,535 22.5
3 (>8% & ≤9%) 3,847 7.8 3,236 8.6






Age < 65 1,058 29.8 1,736 19.6
Age ≥ 65 2,488 70.2 7,110 80.4
Deprivation index
1 618 17.4 1,239 14.0
2 701 19.8 1,650 18.7
3 736 20.8 1,799 20.3
4 747 21.1 1,883 21.3
5 744 21.0 2,275 25.7
Total 3,546 8,846
HbA1c
1 (≤7%) 1,805 65.3 4,491 63.2
2 (>7% & ≤8%) 544 19.7 1,554 21.9
3 (>8% & ≤9%) 236 8.5 574 8.1
4 (>9%) 179 6.5 487 6.9
Total 2,764 7,106
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Among all the population of Basque Country who were
35 or more years old (N = 1,473,937), 126,894 were diag-
nosed with type 2 diabetes (prevalence 8.6%, CI 95%
[8.6, 8.7]) and 76,594 with depression (prevalence 5.2%, CI
95% [5.16, 5.23]). The prevalence of depression among pa-
tients with type 2 diabetes was 9.8% (CI 95% [9.6, 9.9]).
Comparing both sexes, the prevalence was 5.2% (CI 95%
[5.0, 5.3]) for men and was 15.1% (CI 95% [14.9, 15.4]) for
women. There was a relationship between gender and the
comorbidity (p value of Pearson X2 < 0.001). The mean
age between patients who have the comorbidity was
72.9 (CI 05% [72.7, 73.1]).
Among patients with type 2 diabetes and depression,
we could follow up a gradual growth of depression
prevalence from the most affluent layers of population
to the most deprived (see Table 1). The difference be-
tween the richest quintile and the poorest quintile was
around a 1% and there was a relationship between socio-
economic level and the comorbidity (p value of Pearson
X2 < 0.001) for the total, males and females (p < 0.001).
We could also see an increasing gradient in patient’s dis-
tribution by age group, being more prevalent in patients
aged ≥ 65 years than in patients aged < 65 years for dia-
betes type 2 and for the comorbidity. Also, there was
a relationship between age bands and the comorbidity
(p value of Pearson X2 < 0.001).
The Table 1 shows the distribution of these patients by
range of values of HbA1c. The test was carried out in the
76.04% of the patients with diabetes type 2 and without
depression and in the 79.65% of the patients with the co-
morbidity, being the differences between both propor-
tions statistically significant (p < 0.001). Glycaemic control
was better in men than women in all defined groups and
in both populations. The control of HbA1c between pa-
tients with diabetes type 2 and patients with the comorbid-
ity was very similar.
Results of analysis of statistical significance between
presence or absence of depression and HbA1c values
among patients with type 2 diabetes showed that there
was not a general association (Pearson chi2: p = 0.365).
Logistic regression analysis was performed to see if de-
pression in type 2 diabetes population was associated
with the following factors: HbA1c, sex, age band, ADG
and deprivation index. For every man, 2.7 women suf-
fered comorbidity (OR = 2.7; CI 95%: 2.6-2.9). For every
person under 65 years, 1.5 people aged ≥ 65 years suf-
fered it (OR = 1.5; CI 95%: 1.4-1.6). However, glycaemic
control and socioeconomic level were not associated fac-
tors of having depression (see Table 2).
A regression analysis was performed in order to see if
there were statistically significant differences in mean
cost between groups with and without comorbidity of
depression (see Table 3). The R2 was 0.41. R2 is a statisticthat gives information about the goodness of fit of a
model. In regression, the R2 coefficient of determination
is a statistical measure of how well the regression line
approximates the real data points. An R2 of 1 indicates
that the regression line perfectly fits the data. Then, in-
dependent variables explained the 41.2% of the total
variance.
The age band and sex were statistically significant in
the model. People who were ≥ 65 years spent 160€ more
than people who were under 65 years and women spent
179.5€ less than men. In addition, a bad control of HbA1c
Table 2 Logistic regression with odds ratios and
confidence intervals at 95% represented
Depression
Characteristics Odds ratio 95% confidence
interval
HbA1c
HbA1c 1 (referent) 1
HbA1c 2 0.99 0.93, 1.05
HbA1c 3 1.01 0.93, 1.02
HbA1c 4 1.11 0.99, 1.19
Sex
Males (referent) 1
Females 2.71 2.58, 2.86
Deprivation index
Deprivation index 1 (referent) 1
Deprivation index 2 0.95 0.88, 1.03
Deprivation index 3 1.01 0.93, 1.09
Deprivation index 4 0.93 0.86, 1.01
Deprivation index 5 0.96 0.89, 1.03
Age band
Age band < 65 (referent) 1
Age band≥ 65 1.52 1.44, 1.61
This regression analysis was conducted with having depression as comorbidity
as dependent variable and HbA1c, sex, deprivation index, age band and ADGs
as independent variables. As the ADGs are 32 variables, they are not represented
in this table, if you want to know the exact values, please contact to the authors.
Table 3 Linear regression analysis with coefficients and
confidence intervals at 95%
Total cost




HbA1c 2 259.1 195.6, 322.6
HbA1c 3 565.6 470.8, 660.4
HbA1c 4 441.7 335.4, 548.0
Sex
Males (referent)
Females −179.5 −233.6, −125.3
Depression
No (referent)
Yes 515.9 424.2, 607.6
Deprivation index
Deprivation index 1 (referent)
Deprivation index 2 30.0 −58.7, 118.7
Deprivation index 3 90.7 3.4, 178.1
Deprivation index 4 116.8 30.6, 203.0
Deprivation index 5 73.2 −12.5, 158.8
Age band
Age band < 65 (referent)
Age band≥ 65 160.1 103.0, 217.2
This regression analysis was made with total cost as dependent variable and
HbA1c, sex, age band, having depression as comorbidity, deprivation index
and ADGs as independent variables. As the ADGs are 32 variables, they are
not represented in this table, if you want to know the exact values, please
contact to the authors.
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diabetes patients increased the total mean cost, being sta-
tistically significant for each group. Finally, the group 2 and
3 of the deprivation index spent more than the group 1,
90.7€ and 116.8€ more than group 1 respectively.
Discussion
In this study, the prevalence of depression among pa-
tients with type 2 diabetes was 9.8%, 5.2% for men and
15.1% for women. This comorbidity was more prevalent
in the most deprived areas and this prevalence increased
with the age. Our results reported similar prevalence
rate of depression among patients with type 2 diabetes
compared to other published studies. A meta-analysis of
42 published studies found that the prevalence of major
depression among patients with diabetes type 2 was 11%
[10] and Roy T. et al. [14] reported a prevalence of de-
pression two times higher among patients with type 2
diabetes than in general population. In relation to gender,
this meta-analysis [10] also showed high prevalence of de-
pression among females. These differences in prevalence
among the studies are due to the different methods ap-
plied. In addition, Nichols et al. [32] found that people
with diabetes and comorbid depression were more likely
to be women, had lower incomes and health status, andmore diabetes complications. Other study showed that
age, ethnicity and monthly household income were signifi-
cantly associated with depression [33]. So, in line with
other researchers, we also found that female sex and age
was related to depression as comorbidity.
Our logistic analysis has shown that for every man who
suffered comorbidity, there were 2.7 women who suffered
it, which was consistent with the literature. For instance, a
meta-analysis [10] showed that the combined prevalence
was significantly higher in women with diabetes than in
men with diabetes (OR = 1.6, 95% CI: [1.4, 1.8]).
Our study showed that poor glycaemic control was
not associated with a higher prevalence of depression. It
is consistent with other studies that did not find signifi-
cant relationship between glycaemic control and poten-
tial for depression [34-36]. However, Lustman et al. have
found that depression was significantly associated with
poor glycaemic control in individuals with type 1 and
type 2 diabetes [15] and Richardson et al. assessed the
longitudinal effects of depression on glycaemic control
[16]. Moreover, cross- sectional studies found a significant
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tients with type 2 diabetes [37,38].
The total cost was associated with a bad control of
HbA1c, sex, age and depression as comorbidity in pa-
tients who have diabetes type 2. Some studies of health-
care utilization and healthcare costs confirm that the
coexistence of depression among individuals with diabetes
is associated with greater healthcare service utilization and
costs [18,19,32,39].
In our study the comorbid women accounted for less
healthcare costs than men. In study carried out by Burns
et al., total health care costs were higher for males than
females [40]. In addition, Orueta et al. [31] demon-
strated that once adjusted per number of chronic condi-
tions and socioeconomic characteristics, individual cost
for females was lower than for males for all ages but in
the range of 18–44 years old, as expected due to obstet-
ric care.
Our study showed that, on average, people with de-
pression have spent 516€ more than people without de-
pression. Since, regression included ADGs which control
the burden of diseases; this difference could be really at-
tributed to depression (other illness which can have pa-
tients are control by these variables). So, this difference
could be explained by number of reasons such as cost
implications of depression treatment, higher occurrence
and consequent cost of type 2 diabetes complications in
comorbid group [41].
Most authors recognize that depression and diabetes
might have linked pathogenic pathways. Oladeji et al.
[42] discussed in their recent review, that depression
could be explained through the following associated fac-
tors, among others: macrovascular and microvascular
complications of diabetes, disability and presence of co-
morbidities, perceived burden of diabetes, length and
treatment of diabetes, smoking and persistent poor gly-
caemic control.
A current meta-analysis on bidirectional relationship
of diabetes type 2 and depression [13] found that relative
risk increase in incidence of depression in diabetic pa-
tients and vice versa can be associated with biochemical
changes that occur during primary disease. They suggest
that due to small relative and absolute risk differences in
groups with or without one of comorbidities, they might
share common causes and/or risk factors rather than be
associated with each other.
One of the strengths of our study was defined by the
fact that Osakidetza is a tax-funded National Health
System that offers universal coverage to all citizens. This
gave us the possibility to include the entire known dia-
betic population in the geographical area of our study,
thus avoiding selection bias. Moreover, it included cases
of depression that were clinically diagnosed or estimated
through prescriptions because a study carried out in theBasque Country [43] showed that the prevalence calculated
using this combined sources of data was higher than the
obtained from self-reported data in Basque Health Survey.
Also, the data was consistent with previous findings
and utilized a database containing information about pri-
mary care, specialized, outpatient hospital care as well as
prescriptions. This is relevant as other authors have
established that the use of a single source can produce
inaccurate calculations [44,45], while the complementary
use of various sources contributes to a better description
of the health problems of people [43]. Finally, all regres-
sions were controlled through inclusion ADGs in our
analysis, variable that controls the burden of diseases.
The limitations of this study were that administrative
databases only contained information about conditions
for which people looked for medical attention. There-
fore, the prevalence of diabetes and depression may have
reflected only known cases, and excluded the presence
of the cases, that were not known by patients or doctors.
Furthermore, antidepressants can be used for other dif-
ferent pathologies, not only depression, which could lead
to the misidentification of some patients. Moreover, in
this study, the age was limited to equal or more than
35 years and thus we have not estimated the prevalence
of depression among patients with diabetes type 2 in
younger ages. Ganasegeran et al. [33] have showed that
this prevalence is higher in older ages but Zhao et al.
[46] have demonstrated that diabetes is significantly as-
sociated with depression, particularly in young adults.
Also, the cost was calculated in relation to the total
cost of care provided to patients with diabetes type 2,
and it incorporated all the costs related to care of the
disease, but also to other conditions not necessarily re-
lated to it. The non-acute mental health services are not
included. These services account for 2% of the budget of
the Basque Health Service and that have not been con-
sidered in our cost estimations.
Another limitation refers to the social variable used
(deprivation index) which, given its ecological character,
may underestimate the contribution of individual socio-
economic characteristics. Such index was used to classify
geographic areas in quintiles and, although is probable
that actual data relative to unemployment and others
have changed since last census, we consider that the
relative situation of each area with respect to the other
ones has not suffered a substantial alteration. Finally, we
had not access to the type of antidepressants used for
treatment in our study population. Basset et al. [47] also
discuss hyperglycaemic effects of some antidepressants
on diabetes type 2 and thus further research on types of
antidepressants used and their effects on glycaemic con-
trol could be an interesting consideration for future.
In last decade, there has been significant growth in re-
search of association of physical and mental disorders,
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However, this approach still has not been very well
translated to the everyday clinical practice, considering
that diseases are being treated separately in a single-
disease framework, which influences patient adherence
to treatment and clinical outcomes.
Conclusions
Our research has allowed us to obtain an accurate pic-
ture of the prevalence of depression among patients with
diabetes type 2 in the Basque Country. It has also allowed
us to test the relationship between glycaemic control and
prevalence of depression as comorbidity, and its influence
to healthcare costs. Based on our research we can conclude
that poor glycaemic control is not directly associated with
prevalence of depression as comorbidity, but it can be an
important factor of healthcare costs.
Findings of our research, along with results of our lit-
erature overview, highlight the importance of more precise
recognition of depression among diabetic population and
provision of periodic screening and monitoring for depres-
sion among type 2 diabetes patients. Moreover, evidence-
based treatment of depression for diabetic patients should
be included in type 2 diabetes clinical treatment guide-
lines. There is evidence supporting the cost-effectiveness
[50] of interventions tackling type 2 diabetes and depres-
sion through “collaborative care” models.
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